2020-02-20

Jiuzhitang Maker's stem-cell-based new drug receives approval for clinical trials

Great news! Jiuzhitang Maker's stem-cell-based new drug has received approval for clinical trials! This marks the first time the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration has approved a clinical trial using imported stem cells, as well as the first trial employing bone-marrow-derived mesenchymal stem cells. It’s also the first-ever clinical study to explore stem cells as a treatment for major neurological conditions.

+

2020-02-03

New trends, new opportunities — Join us and let your dreams take flight together!

Jiuzhitang Maker is now recruiting distributors nationwide—join us today!

+

2020-01-28

Zhejiang University First Hospital is preparing to use "stem cell therapy" to treat severe cases of novel coronavirus pneumonia!

At Zhejiang University First Hospital, we’ve been using a new approach called stem cell therapy in the treatment of H7N9 avian influenza. Early findings suggest that stem cells show promising results in addressing lung infections and pulmonary fibrosis in avian flu patients. As a result, the hospital’s ethics committee has already approved this innovative treatment, and we’re now preparing to apply it to severe cases of the novel coronavirus.

+

2020-01-23

Jiuzhitang Maker extends New Year greetings: 2020—let’s honor the journey we’ve taken so far and set forth anew with gratitude.

As the vibrant 2020 Spring Festival approaches, Zhang Quancheng, Chairman of Meike Company, and Gao Yansong, General Manager, extend their warmest wishes on behalf of everyone at Jiuzhitang Maker! We sincerely thank each and every friend and family member who has shown care, support, affection, and attention to the growth of Jiuzhitang Maker. Wishing you all a joyful and prosperous New Year!

+

2020-01-23

More great news! Jiuzhitang Maker has secured funding from Beijing's major science and technology project.

Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. recently received significant funding from Beijing's major science and technology project. The company's proposed project, "Preclinical Study of Human Bone Marrow Mesenchymal Stem Cells for the Treatment of Acute Stroke," has been officially approved (Project No. Z191100001519004).

+

2020-01-23

Great news! Jiuzhitang Maker has been honored with the title of "Zhongguancun Golden Seed Enterprise."

On January 14, 2020, the Zhongguancun Science Park Administrative Committee announced the ninth batch of Golden Seed Enterprise名单, and Jiuzhitang Maker was proudly listed!

+

2020-01-14

Jiuzhitang Maker has been honored with the title of "Zhongguancun Golden Seed Enterprise."

Jiuzhitang Maker has been honored with the title of "Zhongguancun Golden Seed Enterprise."

+
< 1...293031...39 >